Jahr Jonathan S, Lurie Fedor, Driessen Bernd, Tang Zuping, Louie Richard F, Kost Gerald
Department of Anesthesiology, University of California Los Angeles, 90095, USA.
Am J Ther. 2003 Jan-Feb;10(1):21-8. doi: 10.1097/00045391-200301000-00006.
This study was designed to validate oxygen saturation measurements from the NOVA CO-Oximeter (NOVA Biomedical Corporation, Waltham, MA), the i-STAT System (Sensor Devices, Waukesha, WI), and the Corning 170 blood gas analyzer (Bayer Corporation, East Walpole, MA) under conditions similar to the clinical application of a hemoglobin-based oxygen carrier (HBOC, hemoglobin glutamer-200 [bovine]; Oxyglobin, Biopure Corporation, Cambridge, MA). A canine model was used for both in vitro and in vivo experiments. In vivo experiments were conducted in a canine laboratory, and in vitro experiments were conducted in a tonometry laboratory. Study subjects were six mixed-breed dogs, each weighing approximately 30 kg. In the first set of experiments, the target blood po(2) levels were reached by tonometry. In the second set of experiments, quantitative measurements of total oxygen content with the LEXO2CON-K (HOSPEX Fiberoptics, Chestnut Hill, MA) were performed, immediately followed by measurements with the NOVA CO-Oximeter and the i-STAT system. HBOC was added in concentrations of 16.2, 32.5, 65, and 97.5 g/L. To analyze the clinical significance of the differences in the results obtained with the each investigated instrument, blood samples from dogs treated with HBOC after acute hemorrhagic shock were used. Oxygen saturation, oxygen content, and po(2) were measured. There was a strong correlation between the oxygen saturation values measured with the investigated instruments in samples after tonometry and known po(2). The total calculated oxygen content varied by 5% based on results generated by calculations using the investigated instruments. The results did not change with different oxygenation of the sample. The differences among methods were not significant when the HBOC concentration was 16.2 g/L. Higher concentrations of HBOC increased the difference between calculated and measured oxygen content; the i-STAT system demonstrated a greater deviation compared with the results of the other two instruments. Systemic oxygen uptake using the investigated instruments showed a high correlation with values based on LEXO2CON-K measurements (R = 0.97 for CO-Oximeter, R = 0.96 for Corning 170 blood gas analyzer, and R = 0.79 for i-STAT system). Systemic oxygen uptake values based on CO-Oximeter and Corning 170 blood gas analyzer data showed 75% accuracy; i-STAT system accuracy was 63% for control samples and 50% for samples after HBOC infusion.
本研究旨在验证在类似于基于血红蛋白的氧载体(HBOC,血红蛋白谷氨酰胺-200[牛];氧球蛋白,Biopure公司,马萨诸塞州剑桥)临床应用的条件下,NOVA CO-血氧计(NOVA生物医学公司,马萨诸塞州沃尔瑟姆)、i-STAT系统(传感器设备公司,威斯康星州沃基肖)和康宁170血气分析仪(拜耳公司,马萨诸塞州东沃尔波尔)的血氧饱和度测量结果。犬类模型用于体外和体内实验。体内实验在犬类实验室进行,体外实验在眼压测量实验室进行。研究对象为6只混种犬,每只体重约30kg。在第一组实验中,通过眼压测量达到目标血氧分压水平。在第二组实验中,使用LEXO2CON-K(HOSPEX光纤公司,马萨诸塞州栗树山)对总氧含量进行定量测量,随后立即使用NOVA CO-血氧计和i-STAT系统进行测量。加入浓度为16.2、32.5、65和97.5g/L的HBOC。为分析各研究仪器所得结果差异的临床意义,使用急性失血性休克后接受HBOC治疗的犬的血样。测量血氧饱和度、氧含量和血氧分压。眼压测量后样本中,各研究仪器测得的血氧饱和度值与已知血氧分压之间存在强相关性。根据各研究仪器计算得出的总氧含量结果相差5%。样本不同氧合状态下结果不变。当HBOC浓度为16.2g/L时,各方法间差异不显著。较高浓度的HBOC增加了计算氧含量与测量氧含量之间的差异;与其他两种仪器的结果相比,i-STAT系统显示出更大偏差。使用各研究仪器测得的全身氧摄取与基于LEXO2CON-K测量值高度相关(CO-血氧计R = 0.97,康宁170血气分析仪R = 0.96,i-STAT系统R = 0.79)。基于CO-血氧计和康宁170血气分析仪数据的全身氧摄取值显示7